PDS Biotechnology
PDSB
68 hedge funds and large institutions have $49.4M invested in PDS Biotechnology in 2023 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 27 increasing their positions, 12 reducing their positions, and 12 closing their positions.
416% more call options, than puts
Call options by funds: $2.5M | Put options by funds: $484K
125% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 12
33% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 12
6% more funds holding
Funds holding: 64 → 68 (+4)
1% more ownership
Funds ownership: 23.92% → 24.93% (+1%)
45% less capital invested
Capital invested by funds: $89.3M → $49.4M (-$39.8M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$1.65M |
| 2 |
Millennium Management
New York
|
+$1.19M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.12M |
| 4 |
Renaissance Technologies
New York
|
+$969K |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$877K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EI
EAM Investors
Solana Beach,
California
|
-$4.36M |
| 2 |
EGI
EAM Global Investors
Solana Beach,
California
|
-$1.61M |
| 3 |
D.E. Shaw & Co
New York
|
-$1.45M |
| 4 |
Morgan Stanley
New York
|
-$981K |
| 5 |
KAM
Knightsbridge Asset Management
Newport Beach,
California
|
-$665K |
PDSB Hedge Fund Activity: Q1 2023 in Review
68 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q1 2023, worth a combined $49.4M — down 45% from $89.3M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new PDSB positions and 12 closed out — a net gain of 4 holders — while 27 added to existing stakes and 12 trimmed.
The largest buyer was Qube Research & Technologies (QRT), opening a new position worth an estimated $1.65M. The largest seller was EAM Investors, exiting entirely with an estimated $4.36M sold.
- 68 institutional investors held PDS Biotechnology (PDSB) as of Q1 2023, up from 64 in Q4 2022.
- Funds reported $49.4M of PDS Biotechnology stock for Q1 2023, down 45% quarter-over-quarter.
- 16 funds opened new PDS Biotechnology positions in Q1 2023 and 12 closed out, a net change of +4 holders.
- The largest PDS Biotechnology buyer in Q1 2023 was Qube Research & Technologies (QRT), an estimated $1.65M added.
- The largest PDS Biotechnology seller in Q1 2023 was EAM Investors, an estimated $4.36M sold.
Based on aggregated 13F filings for Q1 2023.